论坛 › 北京 › 全世界首款mRNA癌症疫苗预计2025年上市，显著延长存活期，国内研发制品层出不穷

j8typz 发表于 2024-5-22 22:59:42

全世界首款mRNA癌症疫苗预计2025年上市，显著延长存活期，国内研发制品层出不穷

    <h1 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNgkuuxfMibtkUcLV7Wcs8RLDGuuC0Giax2K9pwGceLv3IwrGXD451TTdkibvN8Uq7L8tmungOWOth2dw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"><img src="https://mmbiz.qpic.cn/mmbiz_gif/CwkERAMhICzPptxiaua36oPLOf5PYrqeibUVdhbUXQheYSHIicsLg7UcyJh34EHLoRgFnvJevqWRL6gNhvOVJdmMQ/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></span></h1>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">前几年新冠的<span style="color: black;">全世界</span>大流行，让mRNA新冠疫苗顺利出圈，除了预防新冠病毒外，mRNA癌症疫苗在黑色素瘤、非小细胞肺癌等实体瘤治疗<span style="color: black;">行业</span>，<span style="color: black;">一样</span><span style="color: black;">拥有</span>广阔的应用前景。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">近期一款由国际制药巨头默沙东（Merck）和知名疫苗生物<span style="color: black;">机构</span>Moderna联合<span style="color: black;">开发</span>的</span><span style="color: black;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">mRNA-4157疫苗</span></strong></span></span><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">被美国食品<span style="color: black;">药物</span>监督管理局（FDA）授予“<span style="color: black;">突破性治疗指定</span>”，并被欧洲<span style="color: black;">药物</span>管理局授予“<span style="color: black;">优先<span style="color: black;">药品</span>（PRIME）计划</span>”</span></strong><span style="color: black;">，有望<span style="color: black;">作为</span>首款上市的mRNA肿瘤疫苗，</span><strong style="color: blue;"><span style="color: black;">最早或将于2025年<span style="color: black;">面世</span>！</span></strong></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">全世界</span>首款mRNA疗法上市在望，剑指晚期黑色素瘤！</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICy2my0h6TAmLByr7wYXUOvRJScibxNNLyHWiaYbpYK6bFCPbv7NqPyE0ubxTZCCJSHicNicNygCMcUAEg/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲截图源自“</span></span></strong><strong style="color: blue;"><span style="color: black;">ASCO Publications</span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">”</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">mRNA-4157（V940）属于一种mRNA个体化新抗原疗法，由编码多达34种新抗原的合成mRNA<span style="color: black;">构成</span>，旨在<span style="color: black;">按照</span><span style="color: black;">病人</span>肿瘤DNA序列的独特突变特征，产生特定的T细胞反应，来训练和激活抗肿瘤免疫反应，从而达到抗癌目的。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">mRNA-4157<span style="color: black;">这次</span>被FDA授予突破性认定，是基于2023年ASCO会议上，<span style="color: black;">颁布</span>的</span><strong style="color: blue;"><span style="color: black;">mRNA-4157（V940）联合Keytruda（可瑞达，派姆单抗，PD-1<span style="color: black;">控制</span>剂）治疗高危黑色素瘤（III/IV期）的IIb期临床<span style="color: black;">实验</span>结果</span></strong><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">该<span style="color: black;">科研</span>共入组157例</span><strong style="color: blue;"><span style="color: black;">完全切除的高<span style="color: black;">危害</span>Ⅲ B/C/D和Ⅳ期皮肤黑色素瘤<span style="color: black;">病人</span></span></strong><span style="color: black;">，随机被分为两组，即mRNA-4157与派姆单抗联合治疗组（n=107）、派姆单抗单药治疗组(n=50)。中位随访时间为23个月（联合用药）和24个月（派姆单抗单药治疗）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">结果<span style="color: black;">表示</span>，mRNA-4157疫苗联合派姆单抗</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">改善了<span style="color: black;">病人</span>的<span style="color: black;">没</span>复发<span style="color: black;">存活</span>期（RFS）</span></strong></span><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">18个月RFS率（95%CI）为78.6%（联合治疗组） vs 62.2%（单药治疗组）</span></strong><span style="color: black;">；还</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">明显</span>改善了<span style="color: black;">病人</span><span style="color: black;">没</span>远处转移<span style="color: black;">存活</span>期（DMFS）</span></strong></span><span style="color: black;">，</span><strong style="color: blue;"><span style="color: black;">18个月DMFS率（95%CI）为91.8%（联合治疗组） vs 76.8%（单药治疗组）</span></strong><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">总之，与单独<span style="color: black;">运用</span>派姆单抗相比，mRNA-4157疫苗与派姆单抗联用，可<span style="color: black;">明显</span>延长Ⅲ或Ⅳ期黑色素瘤<span style="color: black;">病人</span>的<span style="color: black;">没</span>远处转移<span style="color: black;">存活</span>期，为黑色素瘤<span style="color: black;">病人</span>带来了新的<span style="color: black;">期盼</span>！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>mRNA-4157的Ⅲ期临床<span style="color: black;">实验</span>已<span style="color: black;">起步</span>，旨在<span style="color: black;">评定</span>mRNA-4157与派姆单抗联用，治疗高危（IIB-IV期）黑色素瘤和非小细胞肺癌，并计划<span style="color: black;">快速</span>扩展到其他肿瘤类型。</span></p><strong style="color: blue;"><strong style="color: blue;"><span style="color: black;">怎样</span>寻求mRNA或其他个性化癌症疫苗</strong><strong style="color: blue;"><span style="color: black;">帮忙</span></strong></strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">日前</span>正有两款mRNA癌症疫苗——ABO2011注射液、JCXH-211注射液的临床<span style="color: black;">实验</span>，正在招募恶性实体瘤<span style="color: black;">病人</span>，<span style="color: black;">包含</span>但不限于</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">黑色素瘤、头颈部肿瘤、三阴性乳腺癌、肝癌、食道癌、结直肠癌、肺鳞癌</span></strong></span><span style="color: black;">等。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">若想参加该<span style="color: black;">实验</span>的<span style="color: black;">病人</span>，可将治疗经历、近期病理报告、出院小结等资料，提交至</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部（400-666-7998）</strong></span><span style="color: black;">，进行初步<span style="color: black;">评定</span>。</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">何谓mRNA疫苗？</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICy2my0h6TAmLByr7wYXUOvRlXo7hbH6vWhNZbUF5BKcIreP2FQg8VzXK5cuhf9c1ZSvZ6HIltnQvw/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲</span></span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">图源</span><span style="color: black;">“</span></span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">PMC</span></span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">”，版权归原作者所有，如<span style="color: black;">没</span>意中侵犯了知识产权，请联系<span style="color: black;">咱们</span>删除</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">“mRNA疫苗”全<span style="color: black;">叫作</span>为“信使核糖核酸疫苗”，是一款癌症治疗性疫苗，<span style="color: black;">经过</span>编码表达肿瘤特异性抗原（TAA或TSA）及其<span style="color: black;">关联</span>细胞因子，来激活人体的免疫系统，从而对抗<span style="color: black;">身体</span>的癌细胞。<span style="color: black;">日前</span>适用于</span><strong style="color: blue;"><span style="color: black;">黑色素瘤、结直肠癌（CRC）、非小细胞肺癌（NSCLC）</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">等多款侵袭性、转移性的实体瘤。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">注射mRNA癌症疫苗后，会被递送到抗原呈递细胞[如树突状细胞（DC）]的细胞质中，并在那里被翻译成新抗原蛋白，随后成熟的DC被转运至淋巴结，<span style="color: black;">起步</span>强大的B细胞和T细胞免疫反应，降低肿瘤逃避的可能性，<span style="color: black;">最后</span>达到抗癌目的。</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">胰腺癌“杀手锏”，中位RFS达13.4个月</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICy2my0h6TAmLByr7wYXUOvR5gmEKSl80xLeVH3W7Fx8PUZhxcuPGvnDghwGy3KYiaibSibbibdxSCia7sA/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲截图源自“nature”</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">一款个体化新抗原mRNA疫苗——BNT122（自体cevumeran，RO7198457），能编码超20种不同的特异性新抗原，用于治疗胰腺导管腺癌（PDAC），以降低复发率、延长<span style="color: black;">存活</span>时间。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">BNT122治疗胰腺导管腺癌Ⅰ期临床<span style="color: black;">科研</span>结果，近期已在权威医学期刊《Nature》上<span style="color: black;">发布</span>。在28例接受了手术治疗的胰腺导管腺癌<span style="color: black;">病人</span>中，有19例在术后接受了阿替利珠单抗（Atezolizumab）治疗，其中16例<span style="color: black;">病人</span>随后接种了BNT122疫苗，15例<span style="color: black;">病人</span>随后还接受了改良版四药化疗<span style="color: black;">方法</span>（mFOLFIRINOX，<span style="color: black;">包含</span>亚叶酸、伊立替康、氟尿嘧啶、奥沙利铂）治疗。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">结果<span style="color: black;">表示</span>，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">8例<span style="color: black;">没</span>应答<span style="color: black;">病人</span>的中位<span style="color: black;">没</span>复发<span style="color: black;">存活</span>时间（RFS）为13.4个月</span></strong></span><span style="color: black;">。其中，29号<span style="color: black;">病人</span>的血清CA19-9水平<span style="color: black;">升高</span>，并<span style="color: black;">显现</span>了新的肝脏病变（7mm），但该病灶在随后的<span style="color: black;">影像</span>中消失了，这<span style="color: black;">显示</span></span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">BNT122疫苗可能<span style="color: black;">拥有</span>根除肿瘤微转移的能力</span></strong></span><span style="color: black;">（详见图2）。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">综上，Ⅰ期临床数据<span style="color: black;">显示</span>，BNT122疫苗与阿替利珠单抗+mFOLFIRINOX联合治疗是安全、可行的，且疫苗扩增的T细胞<span style="color: black;">拥有</span>持久性，有利于肿瘤复发的预防。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">图2&nbsp; 接种BNT122疫苗前后<span style="color: black;">病人</span>腹部MRI对比</span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICy2my0h6TAmLByr7wYXUOvR23RmcADNicL7xZCWtONwEq3Z4wNbMRXichZ2Mrpl2Xiaz7EE4Hx0Cn3iaw/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲图源《nature》，版权归原作者所有，如<span style="color: black;">没</span>意中侵犯了知识产权，请联系<span style="color: black;">咱们</span>删除</span></span></strong></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">mRNA癌症疫苗：食管鳞状细胞癌的新<span style="color: black;">选取</span></span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICy2my0h6TAmLByr7wYXUOvRAMibjhgHjtMTbLWgQ0fxaFk2yI7fvBB2cMqSht40SvvCnhfrobOxMYw/640?wx_fmt=png&amp;from=appmsg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">▲截图源</span></span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">自</span><span style="color: black;">“</span></span></strong><strong style="color: blue;"><span style="color: black;">Research Square</span></strong><strong style="color: blue;"><span style="color: black;"><span style="color: black;">”</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">《Research Article》近期<span style="color: black;">报告</span>了个性化mRNA癌症疫苗联合PD-1<span style="color: black;">控制</span>剂，治疗晚期食管鳞状细胞癌的一项临床<span style="color: black;">科研</span>。入组的这例<span style="color: black;">病人</span>，<span style="color: black;">首要</span>接受了食管复发病灶组织样本的全转录组测序，之后<span style="color: black;">经过</span>生物信息学分析，筛选出排名前20的新抗原，并<span style="color: black;">按照</span>这些新抗原筛定制了个性化mRNA癌症疫苗。之后进行了四个周期的mRNA癌症疫苗与PD-1<span style="color: black;">控制</span>剂联合给药，并在治疗前后<span style="color: black;">评定</span><span style="color: black;">病人</span>的免疫反应，<span style="color: black;">同期</span><span style="color: black;">经过</span>影像学<span style="color: black;">检测</span><span style="color: black;">评定</span>病变<span style="color: black;">状况</span>。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">结果<span style="color: black;">表示</span>，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">该<span style="color: black;">病人</span><span style="color: black;">得到</span>了部分缓解（PR），且安全性在可控范围内</span></strong></span><span style="color: black;">，除PD-1<span style="color: black;">控制</span>剂治疗<span style="color: black;">导致</span>的4级血小板减少症外，未观察到其他3级或以上<span style="color: black;">药品</span><span style="color: black;">关联</span>不良事件。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">总之，<span style="color: black;">以上</span>结果<span style="color: black;">显示</span>，</span><strong style="color: blue;"><span style="color: black;">个性化mRNA疫苗疗法与PD-1阻断剂联合应用，可能是晚期食管癌<span style="color: black;">病人</span>的有效治疗策略。</span></strong><span style="color: black;"><span style="color: black;">不外</span><span style="color: black;">日前</span><span style="color: black;">科研</span>范围较局限性，还<span style="color: black;">必须</span><span style="color: black;">得到</span><span style="color: black;">更加多</span>的临床<span style="color: black;">科研</span>证据支持，以证实基于新抗原的个性化免疫疗法，治疗晚期食管鳞癌的有效性和安全性。</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">mRNA癌症疫苗还可治疗<span style="color: black;">那些</span>实体瘤？</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/qXeGgWfP2VvLXGTwgfSlQBZRtUBkp7eA30NYqZZ6NuWQiagL6N7DtXC4JntbgsVaulzBLe1Kb3YKKDic6DuZtpJQ/640?wx_fmt=jpeg&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p><strong style="color: blue;">BNT211：mRNA疫苗联合CAR-T治疗实体瘤，<span style="color: black;">疾患</span><span style="color: black;">掌控</span>率达65%</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">BioNTech<span style="color: black;">机构</span><span style="color: black;">开发</span>的BNT211，是将表达CLDN6抗原的mRNA疫苗，与靶向实体瘤的CAR-T疗法相结合的一种治疗方式。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023年美国临床肿瘤学会（ASCO）上，<span style="color: black;">颁布</span>了BNT211治疗复发/难治性（r/r）实体瘤的1/2a<span style="color: black;">实验</span>结果。在可<span style="color: black;">评定</span>的17例<span style="color: black;">病人</span>中，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">疾患</span><span style="color: black;">掌控</span>率（DCR）达65%，总客观缓解率（ORR）为41%</span></strong></span><span style="color: black;">。其中，5例<span style="color: black;">病人</span>（4例为卵巢癌）达到部分缓解（PR）；3例<span style="color: black;">病人</span>达病情稳定（SD）；另有1例睾丸癌<span style="color: black;">病人</span><span style="color: black;">得到</span>了手术完全缓解。</span></p><strong style="color: blue;">LK101注射液：国内首款获临床IND<span style="color: black;">准许</span>的个性化肿瘤新抗原疫苗</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2023年3月15日，“北京立康生命”自主<span style="color: black;">开发</span>的“LK101注射液”的</span><span style="color: black;">新药临床<span style="color: black;">实验</span>申请（IND），<span style="color: black;">得到</span>国家<span style="color: black;">药物</span>监督管理局<span style="color: black;">药物</span>审评中心（CDE）<span style="color: black;">准许</span></span><span style="color: black;">，用于晚期实体瘤的治疗。它是</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">国内首个<span style="color: black;">获准</span>进入临床<span style="color: black;">周期</span>的个性化肿瘤新生抗原疫苗</span></strong></span><span style="color: black;">，是我国mRNA肿瘤疫苗<span style="color: black;">开发</span>路上的<span style="color: black;">要紧</span>里程碑！</span></p><strong style="color: blue;">JCXH-211：我国首款自复制mRNA疫苗，瘤内注射，远处杀癌！</strong>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">2022年8月16日，嘉晨西海生物技术<span style="color: black;">机构</span>自主<span style="color: black;">开发</span>的“JCXH-211”在国内申报临床，此前该<span style="color: black;">制品</span>已获美国FDA的新药临床<span style="color: black;">实验</span>（IND）批件，</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">是我国首款<span style="color: black;">得到</span>西方<span style="color: black;">重点</span>国家IND批件的mRNA<span style="color: black;">药品</span>，<span style="color: black;">亦</span>是<span style="color: black;">全世界</span>首款表达细胞因子的自复制mRNA疫苗</span></strong></span><span style="color: black;">。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">JCXH-211是一种基于自复制mRNA的编码hIL-12（人白细胞介素-12）的新型<span style="color: black;">药品</span>，用于晚期实体瘤的治疗。JCXH-211已在临床前<span style="color: black;">科研</span>中，<span style="color: black;">表示</span>出良好的肿瘤细胞杀伤力，可消除远端瘤，并预防肿瘤复发，<span style="color: black;">同期</span>安全性良好。</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">JCXH-211将在美国多个临床中心（如MDAnderson癌症<span style="color: black;">科研</span>中心等），<span style="color: black;">起步</span>JCXH-211的I期临床<span style="color: black;">实验</span>，以<span style="color: black;">知道</span>JCXH-211的<span style="color: black;">举荐</span>给药剂量和治疗<span style="color: black;">方法</span>，并<span style="color: black;">评定</span>其耐受性、安全性和初步疗效。</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">博主</span>有话说</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">得益于新冠疫情大流行下的紧急授权<span style="color: black;">运用</span>，mRNA技术的<span style="color: black;">科研</span><span style="color: black;">行业</span>正在<span style="color: black;">快速</span>扩大。mRNA构<span style="color: black;">成为了</span>癌症疫苗的有效且多功能的平台，既可刺激强大的免疫反应，又能降低不良反应，<span style="color: black;">加强</span>机体的抗癌能力！<span style="color: black;">日前</span>在美国国立卫生<span style="color: black;">科研</span>院（NIH）临床<span style="color: black;">实验</span><span style="color: black;">网</span>上收录的<span style="color: black;">处在</span><span style="color: black;">开发</span><span style="color: black;">周期</span>的肿瘤疫苗多达7000余项，其中mRNA疫苗达600余项，<span style="color: black;">另外</span>还<span style="color: black;">包含</span>树突细胞（DC）疫苗等。<span style="color: black;">博主</span><span style="color: black;">亦</span>期望mRNA癌症疫苗能尽快<span style="color: black;">面世</span>，以造福<span style="color: black;">更加多</span>的<span style="color: black;">病人</span>，实现“<span style="color: black;">精细</span>抗癌”的美好愿景！</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">倘若</span>您<span style="color: black;">亦</span>想寻求mRNA或其他个性化癌症疫苗的<span style="color: black;">帮忙</span>，或对<span style="color: black;">日前</span>的治疗存疑，想咨询更合适的治疗<span style="color: black;">方法</span>，可咨询</span><span style="color: black;"><strong style="color: blue;"><span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网医学部（400-666-7998）</strong></span><span style="color: black;">，进行初步<span style="color: black;">评定</span>或申请国际会诊。</span></p><span style="color: black;"><strong style="color: blue;"><span style="color: black;">参考资料</span></strong></span>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Khattak A,et al.Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023.</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA9503</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Ni L.Advances in mRNA-Based Cancer Vaccines. Vaccines (Basel). 2023 Oct 16;11(10):1599.</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611059/</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://investors.modernatx.com/news/news-details/2023/Moderna-And-Merck-Announce-mRNA-4157-V940-In-Combination-with-KeytrudaR-Pembrolizumab-Demonstrated-Continued-Improvement-in-Recurrence-Free-Survival-and-Distant-Metastasis-Free-Survival-in-Patients-with-High-Risk-Stage-IIIIV-Melanoma-Following-Comple/default.aspx</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"></span><span style="color: black;">https://www.researchsquare.com/article/rs-3242165/v1</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;"><span style="color: black;">本文为<span style="color: black;">全世界</span>肿瘤<span style="color: black;">大夫</span>网原创，未经授权严禁转载</span></span></strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">扫描添加病友群</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">抗癌<span style="color: black;">新闻</span>｜新技术｜新药<span style="color: black;">开发</span>｜权威专家</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">入群免费领取抗癌资料</span></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNg6KqSDRGkFCLqIzx6oQdnl7exHOMFNUiaGWodVFjoMtGFRWnyfQlBtZZAz3uklI0QxHUuNPN56bYg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNhVgbg7UqmUKtXibHzFJr0KV2xquiczKpXB4I8TzEfEkmlMhRvM7EhdiacP3SCnRXrlqXf3G2u1K2Zpw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNhd8w4fq9TRJDriaqjuxJGwA6gXLPXAG8sZC1MpAkm08c5FwStlRHwic9jtVsIlgrjdfDXLwGaibNe0A/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoF2lhP7G00eENaJNibbFwd59DKcDLcEVxvFgY8DyrWia98CnlRuuwFPojQ/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFv95zZHMrmhSRdjibbjvSjWdRmBj4jdiaLjOcJ8stJmnYd9N5rALvqvyA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFBg323QAeczRyRJurBGqqQ7Xxm9URicQmTCibfPpR3mlGQyw5VzLfwWqw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFfjclykzqjaBDRibL9ibucVj6P18NC2nHI9p3LnMtTTbJq4FLsveic6lnA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFFlFhOmgkzOCOg7ahVKE3HsjjKic2icJ6fzbqB4bbH0TrQ72kI5YyT5eA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFHRJDibGQrpP8ZSu2KQWROqbasJ6UqTxvuu2T1CTwcf4Ujxn0Hy0bTSg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoF9YvAiad2bw1B2ZzxZVGa5nsZTDRKV3AZDjD95icCof1KqOOHiaZB1poYg/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></a></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/5klfMQpnRNj0Y25r99GfgCV4QWC1yyoFRy3rGic4nsRjibcCf5khPiaVibmibuSucDc8lVAiaXxmB26neVzqribSp25CA/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/sz_mmbiz_png/CwkERAMhICzibJXwMthHxwKov6JricRGq8yvG53iaEWkSIFFvRgXePGUdZCpIJcrgqtht6EJVBic7suVgLWBau4Thw/640?wx_fmt=png&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_gif/5klfMQpnRNgiaJ6y4y3dPq4rQ0ibFxEgHxqGsIJWjTibV9Un6f27jbx22vaMQ0qRRKQbwbe29yLlGWxf9cqvF9c6Q/640?wx_fmt=gif&amp;wxfrom=5&amp;wx_lazy=1&amp;tp=webp" style="width: 50%; margin-bottom: 20px;">

7wu1wm0 发表于 2024-9-26 01:13:10

谷歌外贸网站优化技术。

查看完整版本: 全世界首款mRNA癌症疫苗预计2025年上市，显著延长存活期，国内研发制品层出不穷